BRIEF published on 09/18/2024 at 10:13, 7 months 12 days ago Mirova franchit le seuil des 5% des droits de vote de MEDINCELL Droits De Vote Franchissement De Seuil Actions Medincell Mirova
PRESS RELEASE published on 09/18/2024 at 10:08, 7 months 12 days ago Franchissement de seuil Déclaration de franchissement de seuil par Mirova pour le compte de fonds qu'elle gère concernant MEDINCELL sur Euronext Paris Euronext Paris Franchissement De Seuil Gestion Medincell Mirova
BRIEF published on 09/11/2024 at 07:35, 7 months 19 days ago Medincell establishes a new liquidity contract with Rothschild Martin Maurel Common Shares Euronext Paris Liquidity Contract Rothschild Martin Maurel Medincell
BRIEF published on 09/11/2024 at 07:35, 7 months 19 days ago Medincell établit un nouveau contrat de liquidité avec Rothschild Martin Maurel Euronext Paris Contrat De Liquidité Rothschild Martin Maurel Actions Ordinaires Medincell
PRESS RELEASE published on 09/11/2024 at 07:30, 7 months 19 days ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Medincell appoints ROTHSCHILD MARTIN MAUREL for liquidity contract management on Euronext Paris, complying with AMF Decision 2021-01 Euronext Paris Liquidity Contract Rothschild Martin Maurel AMF Decision Medincell
PRESS RELEASE published on 09/11/2024 at 07:30, 7 months 19 days ago Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité Medincell confie son Contrat de liquidité à ROTHSCHILD MARTIN MAUREL pour animer ses actions sur Euronext Paris, conformément à la réglementation en vigueur Euronext Paris Contrat De Liquidité Rothschild Martin Maurel Réglementation Medincell
BRIEF published on 09/05/2024 at 07:35, 7 months 25 days ago Medincell : avancées prometteuses pour l'Olanzapine injectable Schizophrénie Phase 3 Medincell Olanzapine Teva Pharmaceuticals
BRIEF published on 09/05/2024 at 07:35, 7 months 25 days ago Medincell: Promising advances for injectable Olanzapine Schizophrenia Phase 3 Medincell Olanzapine Teva Pharmaceuticals
PRESS RELEASE published on 09/05/2024 at 07:30, 7 months 25 days ago Inside Information / Other news releases Teva provides update on pivotal Phase 3 of Olanzapine LAI by Medincell. Safety results on track for H2 2024. Potential innovative long-acting antipsychotic treatment Clinical Trials Phase 3 Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/05/2024 at 07:30, 7 months 25 days ago Informations privilégiées / Autres communiqués Teva, partenaire de Medincell, annonce des avancées importantes dans l'essai clinique pivot de phase 3 de l'Olanzapine injectable à durée d’action prolongée, avec un taux élevé d'injections réalisées et des résultats positifs attendus Schizophrénie Essai Clinique Medincell Olanzapine Teva
Published on 05/01/2025 at 02:00, 23 minutes ago EQ Inc. Reports Profitable Fourth Quarter and 2024 Year End Financial Results
Published on 05/01/2025 at 00:00, 2 hours 23 minutes ago Tecogen Announces Uplist to NYSE American Stock Exchange
Published on 04/30/2025 at 23:30, 2 hours 53 minutes ago Arras Minerals Announces Voting Results of Annual and Special Meeting of Shareholders
Published on 04/30/2025 at 23:20, 3 hours 3 minutes ago Justera Health Announces Director Resignation and Change to Fiscal Year End
Published on 04/30/2025 at 23:15, 3 hours 8 minutes ago Interactive Strength Inc. (Nasdaq:TRNR) Provides Shareholder Update on 2025 Developments
Published on 04/30/2025 at 23:30, 2 hours 52 minutes ago EEII AG: Ad-Hoc announcement pursuant to Art. 53 Listing Rules: EEII AG 2024 Annual Results
Published on 04/30/2025 at 22:43, 3 hours 39 minutes ago Assemblée générale ordinaire d’Espace Real Estate Holding AG
Published on 04/30/2025 at 21:15, 5 hours 8 minutes ago voxeljet AG announces financial restructuring with StaRUG procedure after general meeting rejects approval of the sale of the business to Anzu
Published on 04/30/2025 at 21:00, 5 hours 22 minutes ago Northern Data Group issues Business and Operational Update
Published on 04/30/2025 at 20:40, 5 hours 42 minutes ago EQS-Adhoc: Northern Data Group Updates 2025 Guidance and Provides New Guidance Framework
Published on 04/30/2025 at 19:14, 7 hours 8 minutes ago Report de la publication des résultats annuels 2024
Published on 04/30/2025 at 19:14, 7 hours 8 minutes ago Solocal - Communiqué de presse - Mise à disposition du DEU 2024
Published on 04/30/2025 at 18:55, 7 hours 27 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 5, 2025
